Nomura M, Kinoshita S, Satoh H, Maeda T, Murakami K, Tsunoda M, Miyachi H, Awano K
Central Research Laboratories, Kyorin Pharmaceutical Co., Ltd., Tochigi, Japan.
Bioorg Med Chem Lett. 1999 Feb 22;9(4):533-8. doi: 10.1016/s0960-894x(99)00039-6.
A series of 3-[(2,4-dioxothiazolidin-5-yl)methyl]benzamide derivatives was prepared as part of a search for antidiabetic agents. A structure-activity relationship study of these compounds led to the identification of 5-[(2,4-dioxothiazolidin-5-yl)methyl]-2-methoxy-N-[[4-(trifluorome thyl)-phenyl]methyl]benzamide (KRP-297) as a candidate drug for the treatment of diabetes mellitus.
作为寻找抗糖尿病药物工作的一部分，制备了一系列3-[(2,4-二氧代噻唑烷-5-基)甲基]苯甲酰胺衍生物。对这些化合物的构效关系研究导致确定5-[(2,4-二氧代噻唑烷-5-基)甲基]-2-甲氧基-N-[[4-(三氟甲基)-苯基]甲基]苯甲酰胺（KRP-297）为治疗糖尿病的候选药物。
